Indoleamine-2,3-dioxygenase mediates neurobehavioral alterations induced by an intracerebroventricular injection of amyloid-β1-42 peptide in mice

Brain, Behavior, and Immunity

Volumn 56, Issue , 2016, Pages 363-377

  Souza, Leandro Cattelan ^a   Jesse, Cristiano R ^a   Antunes, Michelle S ^a   Ruff, Jossana Rodrigues ^a   de Oliveira Espinosa, Dieniffer ^a   Gomes, Nathalie Savedra ^a   Donato, Franciele ^a   Giacomeli, Renata ^a   Boeira, Silvana Peterini ^a  

^a UNIVERSIDADE FEDERAL DO PAMPA   (Brazil)

Author keywords

Alzheimer's disease; Anxiety; Depression; Indoleamine 2,3 dyoxigenase; Kynurerine; Memory; Neuroinflammation; Neurotrophic factor; Tryptophan

Indexed keywords

1 METHYLTRYPTOPHAN; AMYLOID BETA PROTEIN[1-42]; CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; NEUROTROPHIC FACTOR; TRYPTOPHAN; TRYPTOPHAN DERIVATIVE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); NERVE GROWTH FACTOR; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; ELEVATED PLUS MAZE TEST; EMOTIONAL DISORDER; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; HIPPOCAMPUS; MALE; MEMORY DISORDER; MENTAL TEST; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PREFRONTAL CORTEX; PRIORITY JOURNAL; TAIL SUSPENSION TEST; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INFLAMMATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; METABOLISM; RECOGNITION;

AMYLOID BETA-PEPTIDES; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; INJECTIONS, INTRAVENTRICULAR; KYNURENINE; MEMORY DISORDERS; MICE; NERVE GROWTH FACTORS; PEPTIDE FRAGMENTS; PREFRONTAL CORTEX; RECOGNITION (PSYCHOLOGY); TRYPTOPHAN;

EID: 84961770659     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.03.002     Document Type: Article

References (67)

1. Allen S.J., Watson J.J., Dawbarn D. The neurotrophins and their role in Alzheimer's disease. Curr. Neuropharmacol. 2011, 9:559-573.
2. Allen S.J., Watson J.J., Shoemark D.K., Barua N.U., Patel N.K. GDNF, NGF and BDNF as therapeutic options for neurodegeneration. Pharmacol. Ther. 2013, 138:155-175.
3. Antunes M., Biala G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cognit. Process. 2012, 13:93-110.
4. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011, 377:1019-1031.
5. Bateman R.J., Xiong C., Benzinger T.L.S., Fagan A.M., Goate A., Fox N.C., Marcus D.S., Cairns N.J., Xie X., Blazey T.M., Holtzman D.M., Santacruz A., Buckles V., Oliver A., Moulder K., Aisen P.S., Ghetti B., Klunk W.E., McDade E., Martins R.N., Masters C.L., Mayeux R., Ringman J.M., Rossor M.N., Schofield P.R., Sperling R.A., Salloway S., Morris J.C. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 2012, 367:795-804.
6. Bonda D.J., Mailankot M., Stone J.G., Garrett M.R., Staniszewska M., Castellani R.J., Siedlak S.L., Zhu X., Lee H.G., Perry G., Nagaraj R.H., Smith M.A. Indoleamine 2,3-dioxygenase and 3-hydroxykynurenine modifications are found in the neuropathology of Alzheimer's disease. Redox Rep. 2010, 15:161-168.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principles of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
8. Castagné V., Porsolt R.D., Moser P. Early behavioral screening for antidepressants and anxiolytics. Drug Dev. Res. 2006, 67:729-742.
9. Cerejeira J., Lagarto L., Mukaetova-Ladinska E.B. Behavioral and psychological symptoms of dementia. Front. Neurol. 2012, 3:73.
10. Chambon C., Wegener N., Gravius A., Danysz W. Behavioural and cellular effects of exogenous amyloid-β peptides in rodents. Behav. Brain Res. 2011, 225:623-641.
11. Chen J.H., Ke K.F., Lu J.H., Qiu Y.H., Peng Y.P. Protection of TGF-β1 against neuroinflammation and neurodegeneration in Aβ1-42-induced Alzheimer's disease model rats. PLoS ONE 2015, 10:e0116549. 10.1371/journal.pone.0116549.
12. Cioanca O., Hancianu M., Mihasan M., Hritcu L. Anti-acetylcholinesterase and antioxidant activities of inhaled juniper oil on amyloid Beta (1-42)-induced oxidative stress in the rat hippocampus. Neurochem. Res. 2015, 40:952-960.
13. Clénet F., Bouyon E., Hascoet M., Bourin M. Light/dark cycle manipulation influences mice behavior in the elevated plus maze. Behav. Brain Res. 2006, 166:140-149.
14. Davisson R.L., Yang G., Beltz T.G., Cassell M.D., Johnson A.K., Sigmund C.D. The brain renin-angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Circ. Res. 1998, 83:1047-1058.
15. dos Santos V.V., Santos D.B., Lach G., Rodrigues A.L., Farina M., De Lima T.C., Prediger R.D. Neuropeptide Y (NPY) prevents depressive-like behavior, spatial memory deficits and oxidative stress following amyloid-β (Aβ(1-40)) administration in mice. Behav. Brain Res. 2013, 244:107-115.
16. Eichenbaum H. A cortical-hippocampal system for declarative memory. Nat. Rev. Neurosci. 2000, 1:41-50.
17. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. Behav. Brain Res. 1988, 31:47-59.
18. Fukumoto K., Mizoguchi H., Takeuchi H., Horiuchi H., Kawanokuchi J., Jin S., Mizuno T., Suzumura A. Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment. Behav. Brain Res. 2014, 268:88-93.
19. Gibney S.M., McGuinness B., Prendergast C., Harkin A., Connor T.J. Poly I:C-induced activation of the immune response is accompanied by depression and anxiety-like behaviours, kynurenine pathway activation and reduced BDNF expression. Brain Behav. Immun. 2013, 28:170-181.
20. Goes A.T., Souza L.C., Filho C.B., Del Fabbro L., De Gomes M.G., Boeira S.P., Jesse C.R. Neuroprotective effects of swimming training in a mouse model of Parkinson's disease induced by 6-hydroxydopamine. Neuroscience 2014, 256:61-71.
21. Guillemin G.J., Brew B.J. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. Redox Rep. 2002, 7:199-206.
22. Guillemin G.J., Smythe G.A., Veas L.A., Takikawa O., Brew B.J. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. NeuroReport 2003, 14:2311-2315.
23. Gulaj E., Pawlak K., Bien B., Pawlak D. Kynurenine and its metabolites in Alzheimer's disease patients. Adv. Med. Sci. 2010, 55:204-211.
24. Heisler J.M., O'Connor J.C. Indoleamine 2,3-dioxygenase-dependent neurotoxic kynurenine metabolism mediates inflammation-induced deficit in recognition memory. Brain Behav. Immun. 2015, 50:115-124. 10.1016/j.bbi.2015.06.022.
25. Heneka M.T., Carson M.J., El Khoury J., Landreth G.E., Brosseron F., Feinstein D.L., Jacobs A.H., Wyss-Coray T., Vitorica J., Ransohoff R.M., Herrup K., Frautschy S.A., Finsen B., Brown G.C., Verkhratsky A., Yamanaka K., Koistinaho J., Latz E., Halle A., Petzold G.C., Town T., Morgan D., Shinohara M.L., Perry V.H., Holmes C., Bazan N.G., Brooks D.J., Hunot S., Joseph B., Deigendesch N., Garaschuk O., Boddeke E., Dinarello C.A., Breitner J.C., Cole G.M., Golenbock D.T., Kummer M.P. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015, 14:388-405.
26. Heppner F.L., Ransohoff R.M., Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 2015, 16:358-372.
27. Heyes M.P., Saito K., Major E.O., Milstien S., Markey S.P., Vickers J.H. A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from l-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate. Brain 1993, 116:1425-1450.
28. Holmgren S., Hjorth E., Schultzberg M., Lärksäter M., Frenkel D., Tysen-Bäckström A.C., Aarsland D., Freund-Levi Y. Neuropsychiatric symptoms in dementia-a role for neuroinflammation?. Brain Res. Bull. 2014, 108:88-93.
29. Holsinger R.M., Schnarr J., Henry P., Castelo V.T., Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res. Mol. Brain Res. 2000, 76:347-354.
30. Kincses Z.T., Toldi J., Vécsei L. Kynurenines, neurodegeneration and Alzheimer's disease. J. Cell. Mol. Med. 2010, 14:2045-2054.
31. Lawson M.A., Parrott J.M., McCusker R.H., Dantzer R., Kelley K.W., O'Connor J.C. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J. Neuroinflammation 2013, 18:10-87.
32. Lestage J., Verrier D., Palin K., Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav. Immun. 2002, 16:596-601.
33. Litteljohn D., Mangano E.N., Hayley S. Cyclooxygenase-2 deficiency modifies the neurochemical effects, motor impairment and co-morbid anxiety provoked by paraquat administration in mice. Eur. J. Neurosci. 2008, 28:707-716.
34. Maddison D.C., Giorgini F. The kynurenine pathway and neurodegenerative disease. Semin. Cell Dev. Biol. 2015, 40:134-141.
35. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:702-721.
36. Myint A.M., Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 2003, 61:519-525.
37. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
38. Park H., Poo M.M. Neurotrophin regulation of neural circuit development and function. Nat. Rev. Neurosci. 2013, 14:7-23.
39. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
40. Peters M.E., Schwartz S., Han D., Rabins P.V., Steinberg M., Tschanz J.T., Lyketsos C.G. Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: the cache county dementia progression study. Am. J. Psychiatry 2015, 172:460-465.
41. Piermartiri T.C.B., Figueiredo C.P., Rial D., Duarte F.S., Bezerra S.C., Mancini G., De Bem A.F., Prediger R.D.S., Tasca C.I. Atorvastatin prevents hippocampal cell death, neuroinflammation and oxidative stress following amyloid-β1-40 administration in mice: evidence for dissociation between cognitive deficits and neuronal damage. Exp. Neurol. 2010, 226:274-284.
42. Porter R.J., Lunn B.S., Walker L.L., Gray J.M., Ballard C.G., O'Brien J.T. Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. Am. J. Psychiatry 2000, 157:638-640.
43. Porter R.J., Lunn B.S., O'Brien J.T. Effects of acute tryptophan depletion on cognitive function in Alzheimer's disease and in the healthy elderly. Psychol. Med. 2003, 33:41-49.
44. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 2003, 463:3-33.
45. Rammes G., Gravius A., Ruitenberg M., Wegener N., Chambon C., Sroka-Saidi K., Jeggo R., Staniaszek L., Spanswick D., O'Hare E., Palmer P., Kim E.M., Bywalez W., Egger V., Parsons C.G. MRZ-99030 - a novel modulator of Aβ aggregation: II - reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice. Neuropharmacology 2015, 92:170-182.
46. Rosenberg P.B., Nowrangi M.A., Lyketsos C.G. Neuropsychiatric symptoms in Alzheimer's disease: what might be associated brain circuits?. Mol. Aspects Med. 2015, 43-44:25-37.
47. Salazar A., Gonzalez-Rivera B.L., Redus L., Parrott J.M., O'Connor J.C. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm. Behav. 2012, 62:202-209.
48. Shin M.K., Kim H.G., Baek S.H., Jung W.R., Park D.I., Park J.S., Jo D.G., Kim K.L. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques. Neurobiol. Aging 2014, 35:990-1001.
49. Silva N.M., Rodrigues C.V., Santoro M.M., Reis L.F., Alvarez-Leite J.I., Gazzinelli R.T. Expression of indoleamine 2,3-dioxygenase, tryptophan degradation, and kynurenine formation during in vivo infection with Toxoplasma gondii: induction by endogenous gamma interferon and requirement of interferon regulatory factor 1. Infect. Immun. 2002, 70:859-868.
50. Sopova K., Gatsiou K., Stellos K., Laske C. Dysregulation of neurotrophic and haematopoietic growth factors in Alzheimer's disease: from pathophysiology to novel treatment strategies. Curr. Alzheimer Res. 2014, 11:27-39.
51. 1-40 peptide. Neurotox. Res. 2013, 24:148-163.
52. Spijker S. Dissection of rodent brain regions. Neuroproteomics (Neuromethods) 2011, 13-26. Springer Science+Business Media, LLC.
53. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
54. Stone T.W., Darlington L.G. Endogenous kynurenines as targets for drug. Nat. Rev. Drug Discov. 2002, 1:609-620.
55. Szczepanik A.M., Ringheim G.E. IL-10 and glucocorticoids inhibit Abeta(1-42)- and lipopolysaccharide-induced pro-inflammatory cytokine and chemokine induction in the central nervous system. J. Alzheimers Dis. 2003, 5:105-117.
56. Takeda S., Sato N., Morishita R. Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. Front. Aging Neurosci. 2014, 29(6):171.
57. Tan L., Yu J.T., Tan L. The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J. Neurol. Sci. 2012, 323:1-8.
58. Van Dam D., De Deyn P.P. Animal models in the drug discovery pipeline for Alzheimer's disease. Br. J. Pharmacol. 2011, 164:1285-1300.
59. Wang W.Y., Tan M.S., Yu J.T., Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. Ann. Transl. Med. 2015, 3:136. 10.3978/j.issn.2305-5839.2015.03.49.
60. Warburton E.C., Brown M.W. Neural circuitry for rat recognition memory. Behav. Brain Res. 2015, 285:131-139.
61. Williams R.W. The Mouse Brain Library 1999, http://www.mbl.org/atlas165/atlas165_start.html.
62. Winters B.D., Saksida L.M., Bussey T.J. Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neurosci. Biobehav. Rev. 2008, 32:1055-1070.
63. Wu W., Nicolazzo J.A., Wen L., Chung R., Stankovic R., Bao S.S., Lim C.K., Brew B.J., Cullen K.M., Guillemin G.J. Expression of tryptophan 2,3-dioxygenase and production of kynurenine pathway metabolites in triple transgenic mice and human Alzheimer's disease brain. PLoS ONE 2013, 8:e59749. 10.1371/journal.pone.0059749.
64. Xie W., Cai L., Yu Y., Gao L., Xiao L., He Q., Ren Z., Liu Y. Activation of brain indoleamine 2,3-dioxygenase contributes to epilepsy-associated depressive-like behavior in rats with chronic temporal lobe epilepsy. J. Neuroinflammation 2014, 11:41.
65. Yamada A., Akimoto H., Kagawa S., Guillemin G.J., Takikawa O. Proinflammatory cytokine interferon-gamma increases induction of indoleamine2,3-dioxygenase in monocytic cells primed with amyloid beta peptide 1-42: implications for the pathogenesis of Alzheimer's disease. J. Neurochem. 2009, 110:791-800.
66. Yan J.J., Cho J.Y., Kim H.S., Kim K.L., Jung J.S., Huh S.O., Suh H.W., Kim Y.H., Song D.K. Protection against beta-amyloid peptide toxicity in vivo with long-term administration of ferulic acid. Br. J. Pharmacol. 2001, 133:89-96.
67. Zhang F., Jiang L. Neuroinflammation in Alzheimer's disease. Neuropsychiatric Dis. Treat. 2015, 11:243-256.